Mantle cell lymphoma: trials for referral
158 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Mantle cell lymphoma·What we know·Glossary·Tumour board sheet
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
158 trials shown
Phase 10 sites
Not yet recruiting
NCT07444710
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
National Cancer Institute (NCI)
Pre-treatment window Registry sentence: “Patients must have histologically or cytologically confirmed previously untreated mantle cell lymphoma which is stage II bulky, stage III, or stage IV and fit for intensive chemotherapy.”
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 383 sites
RecruitingAustralia, Brazil, Canada, China, Spain, France
NCT06084936
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Hoffmann-La Roche
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 151 sites
RecruitingAustralia, Canada, Germany, Denmark, Spain, France
NCT07101328
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Eli Lilly and Company
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 27 sites
Not yet recruitingUnited States
NCT07799220
A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT03125642
Auto Stem Cell Transplant for Lymphoma Patients
Masonic Cancer Center, University of Minnesota
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 113 sites
RecruitingAustralia, Canada, Spain, Italy, United States
NCT05365659
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Iksuda Therapeutics Ltd.
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT06054776
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
City of Hope Medical Center
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 3242 sites
RecruitingUnited States
NCT05976763
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology
Pre-treatment window Registry sentence: “No prior systemic treatment for mantle cell lymphoma”
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingUnited States
NCT07910435
Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial
University of Washington
Pre-treatment window Registry sentence: “Prior systemic therapy for MCL”
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 128 sites
RecruitingAustralia, Spain, France, Italy, Poland, United States
NCT07691606
A Study of ARC-02 in B-cell NHL
Taiho Oncology, Inc.
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 211 sites
RecruitingUnited States
NCT07003295
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
National Cancer Institute (NCI)
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT06839053
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Fred Hutchinson Cancer Center
Pre-treatment window Registry sentence: “For the treatment-naïve cohort, patients should have no prior treatment for CLL/SLL (other than 1 aborted regimen \< 2 weeks in duration and \> 4 weeks before enrollment)”
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 14 sites
RecruitingChina
NCT04807881
Phase Ib Clinical Study of Keynatinib
Medolution Ltd.
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 3148 sites
RecruitingArgentina, Austria, Australia, Brazil, China, Germany
NCT06742996
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
BeOne Medicines
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 1/259 sites
RecruitingAustralia, China, Czechia, Germany, Denmark, Spain
NCT06564038
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
AstraZeneca
Pre-treatment window Registry sentence: “Histologically confirmed diagnosis of previously untreated large B-cell Lymphoma (LBCL) per WHO 2022.”
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 217 sites
RecruitingSpain
NCT07029737
A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain
AstraZeneca
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 1/211 sites
RecruitingUnited States
NCT06533579
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics Inc.
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 1/225 sites
RecruitingAustralia, Brazil, China, Spain, France, United Kingdom
NCT06697184
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
BeOne Medicines
Pre-treatment window Registry sentence: “Prior systemic treatment for the CLL”
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT04545762
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
C. Babis Andreadis
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 1/23 sites
RecruitingUnited States
NCT05861050
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
City of Hope Medical Center
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT07892027
Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy
University of Michigan Rogel Cancer Center
Registry updated 23 Oct 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingUnited States
NCT07578077
Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
City of Hope Medical Center
Registry updated 22 Oct 2026
Registry record: ClinicalTrials.govPhase 1/229 sites
RecruitingChina
NCT05294731
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
BeOne Medicines
Registry updated 21 Oct 2026
Registry record: ClinicalTrials.govPhase 16 sites
RecruitingChina, United States
NCT07424833
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ascentage Pharma Group Inc.
Registry updated 15 Oct 2026
Registry record: ClinicalTrials.govPhase 17 sites
RecruitingCanada
NCT06208735
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
British Columbia Cancer Agency
Registry updated 14 Oct 2026
Registry record: ClinicalTrials.govPhase 25 sites
RecruitingCanada
NCT07341191
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
Canadian Cancer Trials Group
Registry updated 14 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT06675123
Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
City of Hope Medical Center
Registry updated 14 Oct 2026
Registry record: ClinicalTrials.govPhase 1/24 sites
RecruitingUnited States
NCT03523975
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
City of Hope Medical Center
Registry updated 14 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT06026319
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Marcela V. Maus, M.D.,Ph.D.
Registry updated 9 Oct 2026
Registry record: ClinicalTrials.govPhase 1/2114 sites
RecruitingAustralia, Brazil, Canada, China, Germany, Spain
NCT05006716
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
BeOne Medicines
Registry updated 5 Oct 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States82 open trials
- China41 open trials
- Spain20 open trials
- France17 open trials
- Italy17 open trials
- Australia13 open trials
- Germany11 open trials
- United Kingdom10 open trials
- Canada9 open trials
- Poland7 open trials
- South Korea6 open trials
- Sweden5 open trials
- Denmark5 open trials
- Japan5 open trials
- Brazil4 open trials
- Czechia4 open trials
- Taiwan3 open trials
- Moldova3 open trials
- Romania3 open trials
- Netherlands3 open trials
- Puerto Rico2 open trials
- Austria2 open trials
- Türkiye2 open trials
- Georgia2 open trials
- Ukraine2 open trials
- Belgium2 open trials
- Switzerland2 open trials
- New Zealand1 open trial
- Argentina1 open trial
- Greece1 open trial
- Croatia1 open trial
- Hungary1 open trial
- Portugal1 open trial
- Norway1 open trial
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
Turin, Italy
1 trial · 9 publications · ROR
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Brescia, Italy
9 trials · 8 publications · ROR
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
Milan, Italy
15 trials · 8 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
Status changed: Completed → Running, not recruiting
NCT06667687 · Phase 1 · Australia, Denmark, Spain, United Kingdom, Israel, Japan
Source: ClinicalTrials.govClosed for recruitment
NCT05458297 · Phase 2 · Brazil, Canada, Chile, China, Czechia, Germany
Source: ClinicalTrials.govPhase changed: Phase 1/2 → Phase 2
NCT05283720 · Phase 2 · China, Czechia, Germany, Denmark, Spain, France
Source: ClinicalTrials.govOpened for recruitment
DALY II USA/ MB-CART2019.1 for DLBCL
NCT04792489 · Phase 2 · Canada, Croatia, Hungary, United States
Source: ClinicalTrials.govPhase changed: Phase 2/3 → Phase 3
NCT04002297 · Phase 3 · Austria, Australia, Belgium, Canada, China, Germany
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
NCT02213926 · Phase 2 · Australia, Belgium, Czechia, Spain, France, United Kingdom
Source: ClinicalTrials.govOpened for recruitment
NCT05458297 · Phase 2 · Brazil, Canada, Chile, China, Czechia, Germany
Source: ClinicalTrials.govClosed for recruitment
DALY II USA/ MB-CART2019.1 for DLBCL
NCT04792489 · Phase 2 · Canada, Croatia, Hungary, United States
Source: ClinicalTrials.gov
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
No phaseEnded Sept 2026
Withdrawn before start0 participants
NCT04231734
Ketogenic Diet in Patients With Untreated Low Tumor Burden Mantle Cell Lymphoma
Reason given: Low accrual
Phase 1/2Ended 28 Aug 2026
Completed36 participants
NCT03015896
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Phase 2Ended 21 May 2026
Stopped early11 participants
NCT05453396
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
Reason given: The trial closed early due to slow accrual.
No phaseEnded 14 May 2026
Stopped early200 participants
NCT01962636
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Reason given: No longer a research question to answer.
Phase 1Ended 2 Mar 2026
Phase 1Ended 13 Feb 2026
Completed25 participants
NCT00641381
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
Phase 1Ended 21 Jan 2026
Completed86 participants
NCT05665530
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Phase 2Ended 9 Jan 2026
Phase 2Ended 5 Jan 2026
Phase 2Ended 29 Dec 2025
Completed87 participants
NCT04849416
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
Phase 1/2Ended 23 Dec 2025
Completed803 participants
NCT03740529
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
- Population pharmacokinetic analysis of pirtobrutinib, a non-covalent BTK inhibitor, in patients with hematological malignancies from the Phase 1/2 BRUIN study. · Cancer chemotherapy and pharmacology, 2026
- Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial. · The Lancet. Haematology, 2026
- Final Analysis of the BRUIN Phase 1/2 Study Assessing the Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCL. · American journal of hematology, 2026
Phase 3Ended 22 Dec 2025
Completed832 participants
2024-511235-10-00
autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial
Phase 1Ended 24 Nov 2025
Completed35 participants
NCT02568553
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
Phase 1/2Ended 30 Oct 2025
Completed40 participants
NCT02328014
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
Phase 1/2Ended 27 Oct 2025
Completed161 participants
NCT02362035
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Phase 2Ended 15 Oct 2025
Completed141 participants
NCT03567876
Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL
Phase 1Ended 6 Oct 2025
Completed16 participants
NCT04488354
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Phase 1Ended 1 Aug 2025
Completed50 participants
NCT02996773
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
No phaseEnded 11 Jul 2025
Phase 3Ended 30 Jun 2025
Show more
Phase 1/2Ended 30 Jun 2025
Completed55 participants
NCT04172246
Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies
Phase 2Ended 17 Jun 2025
Completed95 participants
NCT04880434
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)
Phase 2Ended 30 May 2025
Completed25 participants
NCT00878254
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Phase 2Ended 28 May 2025
Phase 2Ended 21 May 2025
Completed68 participants
NCT02601313
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (ZUMA-2)
- Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma. · Blood advances, 2026
- Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2. · Journal of hematology & oncology, 2026
Phase 2Ended 21 May 2025
Completed67 participants
NCT04703686
Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
Phase 2Ended 14 May 2025
Stopped early7 participants
NCT05025423
Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma
Reason given: The study sponsor withdrew funding early, forcing this study to stop all activity and close pre-maturely.
Phase 1/2Ended 13 May 2025
Completed48 participants
NCT02558816
A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients
Phase 2Ended 3 May 2025
Stopped early150 participants
NCT03246906
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Reason given: Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and Data Safety Monitoring Board recommendations.
Phase 1Ended 22 Apr 2025
Completed15 participants
NCT03939182
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
Phase 2Ended 14 Apr 2025
Completed13 participants
NCT03623373
Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
Phase 2Ended 11 Apr 2025
Stopped early3 participants
NCT04047797
Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Reason given: Administratively Complete 75%\<Participants
Phase 1Ended 30 Mar 2025
Stopped early1 participant
NCT06256484
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Reason given: Financial reasons
Phase 2Ended 24 Mar 2025
Completed78 participants
NCT02988466
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
No phaseEnded 21 Feb 2025
Phase 1Ended 21 Feb 2025
Completed8 participants
NCT04578600
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
Phase 1Ended 3 Feb 2025
Stopped early34 participants
NCT04735471
A Phase 1 Study of ADI-001 in B Cell Malignancies
Reason given: Terminated - Halted Prematurely
Phase 3Ended 31 Jan 2025
Completed623 participants
NCT01865110
R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL
Phase 1Ended 3 Jan 2025
Stopped early1 participant
NCT06343376
Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies
Reason given: Manufacturing issues
Phase 1Ended 31 Dec 2024
Withdrawn before start0 participants
NCT04635683
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Reason given: Investigational Drug removed from the market
Phase 1/2Ended 20 Dec 2024
Completed169 participants
NCT03997968
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Phase 2Ended 19 Dec 2024
Completed135 participants
NCT00719888
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Phase 2Ended 10 Dec 2024
Phase 2Ended 2 Dec 2024
Completed86 participants
NCT02896582
Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance
No phaseEnded 1 Dec 2024
Phase 1Ended 11 Nov 2024
Completed110 participants
NCT02635672
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Phase 1/2Ended 29 Oct 2024
Completed55 participants
NCT02213913
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
Phase 2Ended 25 Oct 2024
Completed30 participants
NCT05008055
Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Phase 1/2Ended 16 Oct 2024
Stopped early19 participants
NCT06106841
TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Reason given: Study terminated for strategic business reasons
Phase 1Ended 10 Oct 2024
Completed14 participants
NCT03410901
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas
No phaseEnded 1 Oct 2024
Completed39 participants
NCT04833504
Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma
Phase 2Ended 26 Sept 2024
Completed36 participants
NCT05564052
A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
Phase 1/2Ended 25 Sept 2024
Completed95 participants
NCT03088878
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
Phase 3Ended 17 Sept 2024
Phase 1/2Ended 12 Sept 2024
Stopped early9 participants
NCT05588440
A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
Reason given: Based on the available clinical data and capital requirements for continued development, the Company has decided to terminate this study.
Phase 1/2Ended 28 Aug 2024
Completed97 participants
NCT04282018
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
Phase 2Ended 1 Aug 2024
Stopped early4 participants
NCT05788289
A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma
Reason given: Slow accrual rate
Phase 2Ended 30 Jul 2024
Completed29 participants
NCT04716075
Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
Phase 2Ended 26 Jul 2024
Completed33 participants
NCT03834688
Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age
Phase 1Ended 24 Jul 2024
Stopped early84 participants
NCT03547115
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
Reason given: Business reasons, not related to safety or efficacy results.
Not medical advice. fetched 9 Nov 2026